Third Quarter 2026 worldwide revenue of $154.5 million, an increase of 15.0% year over year
Profitability expansion in the Third Quarter 2026, with net income of $4.1 million and adjusted EBITDA of $26.8
AtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the
AtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will
NEW YORK, Sept. 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P 100, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of
AtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the
MINNEAPOLIS, July 27, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP), a medical technology company focused on innovative, minimally invasive solutions for patients with obstructive sleep apnea
AtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the
Second Quarter 2026 worldwide revenue of $153.6 million, an increase of 12.8% year over year
Second Quarter 2026 profitability strengthened, with net income of $9.0 million and adjusted EBITDA of $27.3
AtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will
First Quarter 2026 worldwide revenue of $141.2 million, an increase of 14.3% year over year
First Quarter 2026 profitability improved, with net income of $0.1 million and adjusted EBITDA of $17.1 million
U.S.
Fourth Quarter 2025 worldwide revenue of $140.5 million – an increase of 13.1% year over year
Fourth Quarter 2025 net income of $1.8 million and positive adjusted EBITDA of $19.9 million
Full Year 2025 worldwide
